Products by Johnson and Johnson

Johnson & Johnson Secures FDA Approval For Nasal Spray

Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray,

Fox Business · 2d

J&J's ketamine-derived nasal spray approved by FDA to treat depression

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.

MT Newswires on MSN · 2d

Johnson & Johnson Secures FDA Approval For Nasal Spray as Depression Monotherapy

Johnson & Johnson (JNJ) said Tuesday that the US Food and Drug Administration approved nasal spray Spravato as the first-ever stand-alone therapy for major depressive disorder. The product, which targets the glutamate neurotransmitter in the brain,

WAVY Norfolk on MSN · 2d

Nose spray to treat depression? FDA approves first-of-its-kind medicine

The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday.

Johnson & Johnson posts Q4 beat

The Motley Fool · 1d

Johnson & Johnson Tops Q4 EPS Forecasts

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

Business Insider · 1d

Johnson & Johnson Q4 Profit Decreases, But Beats Estimates

Johnson & Johnson (JNJ) announced a profit for fourth quarter that decreased from last year but beat the Street estimates. The

AOL · 1d

Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings

Johnson & Johnson beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to about $143 per share. Several negative impacts were highligh

20h

Johnson & Johnson: Hold Rating Amid Mixed Performance and Future Uncertainties

Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...

The Motley Fool1d

Johnson & Johnson (NYSE: JNJ)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments ...

4hon MSN

Johnson & Johnson's SWOT analysis: oncology portfolio drives growth amid challenges

Johnson & Johnson (NYSE:JNJ), a global healthcare giant, continues to navigate a complex landscape of opportunities and ...

10don MSN

Johnson & Johnson Acquires Intra-Cellular in $14.6 Billion Deal

Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...

MassDevice1d

Johnson & Johnson MedTech sales grow 6.2% in 2025, driven by EP, Abiomed

Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...

Johnson & Johnson sees 2H25 operational sales growth higher than 1H25

Expects more pronounced impact from newly launched products as the year progresses. STELARA biosimilar competition to ...

Johnson & Johnson: Q4 Earnings Snapshot

Johnson & Johnson expects full-year earnings in the range of $10.50 to $10.70 per share, with revenue in the range of $89.2 billion to $90 billion. This story was generated by Automated Insights ( ...

Hosted on MSN1d

Johnson & Johnson Issues Guidance for Higher 2025 Results Following Fourth-Quarter Beat

Johnson & Johnson's (JNJ) fourth-quarter results topped market expectations while the healthcare products conglomerate anticipates results in 2025 to be higher than the previous year. The company sees ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results